Table 1.
Univariate analysis for association of baseline participant characteristics with visual outcomes at 1 year
| # of Subjects at 1 Year (N=1105) | VA score at 1 year | Change in VA score at 1 year | ≥3-lines gain from baseline at 1 year | ||||
|---|---|---|---|---|---|---|---|
| Baseline Participant Characteristics | n(%) | Mean (SE) | P-value* | Mean (SE) | P-value* | n(%) | P-Value† |
| Age (years) | <0.001 | 0.02 | 0.03 | ||||
| 50–69 | 131 (11.9%) | 74.6 (1.5) | 10.9 (1.3) | 51 (38.9%) | |||
| 70–79 | 387 (35.0%) | 70.3 (0.9) | 7.3 (0.7) | 107 (27.6%) | |||
| 80–89 | 512 (46.3%) | 65.2 (0.8) | 6.4 (0.7) | 141 (27.5%) | |||
| ≥90 | 75 (6.8%) | 64.0 (2.0) | 7.6 (1.7) | 28 (37.3%) | |||
| As continuous (1 year increase) | −0.50 (0.07) | <0.001 | −0.18 (0.06) | 0.002 | 0.11 | ||
| Gender | 0.31 | 0.30 | 0.25 | ||||
| Female | 684 (61.9%) | 68.4 (0.7) | 7.7 (0.6) | 211 (30.8%) | |||
| Male | 421 (38.1%) | 67.3 (0.9) | 6.7 (0.7) | 116 (27.6%) | |||
| Cigarette Smoking | 0.75 | 0.93 | 0.74 | ||||
| Never | 475 (43.0%) | 68.2 (0.8) | 7.4 (0.7) | 140 (29.5%) | |||
| Quit | 536 (48.5%) | 68.1 (0.8) | 7.3 (0.6) | 156 (29.1%) | |||
| Current | 94 (8.5%) | 66.7 (1.8) | 6.8 (1.5) | 31 (33.0%) | |||
| Hypertension | 0.03 | 0.41 | 0.32 | ||||
| No | 346 (31.3%) | 69.7 (1.0) | 7.9 (0.8) | 95 (27.5%) | |||
| Yes | 759 (68.7%) | 67.3 (0.7) | 7.1 (0.5) | 232 (30.6%) | |||
| Diabetes | 0.67 | 0.73 | 0.39 | ||||
| No | 915 (82.8%) | 68.1 (0.6) | 7.4 (0.5) | 276 (30.2%) | |||
| Yes | 190 (17.2%) | 67.5 (1.3) | 7.0 (1.1) | 51 (26.8%) | |||
| Treatment Group | 0.45 | 0.16 | 0.09 | ||||
| Ranibizumab Monthly | 284 (25.7%) | 68.8 (1.05) | 8.5 (0.8) | 97 (34.2%) | |||
| Bevacizumab Monthly | 265 (24.0%) | 68.4 (1.09) | 8.0 (1.0) | 83 (31.3%) | |||
| Ranibizumab as needed | 285 (25.8%) | 68.4 (1.05) | 6.8 (0.8) | 71 (24.9%) | |||
| Bevacizumab as needed | 271 (24.5%) | 66.5 (1.08) | 5.9 (1.0) | 76 (28.0%) | |||
VA=Visual Acuity; SE = Standard Error;
*
P-value was from one-way analysis of variance (ANOVA).
†
P value was from Monte-Carlo fisher exact test.
P-value in the parenthesis was calculated with category of unknown into comparison, while P-value not in the parenthesis was calculated excluding category of unknown into comparison.